Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

Postoperative Adjuvant Chemoradiotherapy in Rectal Cancer

직장암의 근치적 수술 후 보조 화학방사선요법

  • Chang, Sei-Kyung (Departments of Radiation Oncology, Bundang CHA General Hospital, Pochon CHA University) ;
  • Kim, Jong-Woo (Department of Surgery Bundang, CHA General Hospital, Pochon CHA University) ;
  • Oh, Do-Yeun (Department of Internal Medicine, Bundang CHA General Hospital, Pochon CHA University) ;
  • Chong, So-Young (Department of Internal Medicine, Bundang CHA General Hospital, Pochon CHA University) ;
  • Shin, Hyun-Soo (Departments of Radiation Oncology, Bundang CHA General Hospital, Pochon CHA University)
  • 장세경 (포천중문의과대학교 분당차병원 방사선종양학과) ;
  • 김종우 (포천중문의과대학교 분당차병원 외과) ;
  • 오도연 (포천중문의과대학교 분당차병원 내과) ;
  • 정소영 (포천중문의과대학교 분당차병원 내과) ;
  • 신현수 (포천중문의과대학교 분당차병원 방사선종양학과)
  • Published : 2006.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

[ $\underline{Purpose}$ ]: To evaluate the role of postoperative adjuvant chemoradiotherapy in rectal cancer, we retrospectively analyzed the treatment outcome of patients with rectal cancer taken curative surgical resection and postoperative adjuvant chemoradiotherapy. $\underline{Materials\;and\;Methods}$: A total 46 patients with AJCC stage II and III carcinoma of rectum were treated with curative surgical resection and postoperative adjuvant chemoradiotherapy. T3 and T4 stage were 38 and 8 patients, respectively. N0, N1, and N2 stage were 12, 16, 18 patients, respectively. Forty patients received bolus infusions of 5-fluorouracil ($500\;mg/m^2/day$) with leucovorin ($20\;mg/m^2/day$), every 4 weeks interval for 6 cycles. Oral Uracil/Tegafur on a daily basis for $6{\sim}12$ months was given in 6 patients. Radiotherapy with 45 Gy was delivered to the surgical bed and regional pelvic lymph node area, followed by $5.4{\sim}9\;Gy$ boost to the surgical bed. The follow up period ranged from 8 to 75 months with a median 35 months. $\underline{Results}$: Treatment failure occurred in 17 patients (37%). Locoregional failure occurred in 4 patients (8.7%) and distant failure in 16 patients (34.8%). There was no local failure only. Five year actuarial overall survival (OS) was 51.5% and relapse free survival (RFS) was 58.7%. The OS and RFS were 100%, 100% in stage N0 patients, 53.7%, 47.6% in N1 patients, and 0%, 41.2% in N2 patients (p=0.012, p=0.009). The RFS was 55%, 78.5%, and 31.2% in upper, middle, and lower rectal cancer patients, respectively (p=0.006). Multivariate analysis showed that N stage (p=0.012) was significant prognostic factor for OS and that N stage (p=0.001) and location of tumor (p=0.006) were for RFS. Bowel complications requiring surgery occurred in 3 patients. $\underline{Conclusion}$: Postoperative adjuvant chemoradiotherapy was an effective modality for locoregional control of rectal cancer. But further investigations for reducing the distant failure rate are necessary because distant failure rate is still high.

목 적: 직장암으로 근치적 수술 후 보조 화학방사선요법을 시행받은 환자들의 치료실패 양상 및 생존율 등의 치료 결과를 후향적으로 확인함으로써 직장암 환자의 치료에서 근치적 수술 후 보조 화학방사선요법의 역할을 알아보고자 하였다. 대상 및 방법: 직장암으로 근치적 수술을 시행하고 수술 후 보조 치료방법으로 화학방사선치료를 시행받은 AJCC 병기 II기와 III기 환자 46명을 대상으로 하였다. 병기별 분포는 T1, T2 병기는 없었고 T3 38명(82.6%), T4 8명(17.4%)으로 대부분 T3 병기였으며, N0 12명(26.1%), N1 16명(34.8%), N2 18명(39.1%)이었다. 보조 화학요법은 40명에서 4주 간격으로 6회에 걸쳐 5-fluorouracil (5-Fu)와 leucovorin을 정맥 주사하였고 6명에서는 Uracil/Tegafur (UFT)를 $6{\sim}12$개월간 매일 경구 복용하였다. 방사선치료는 골반 내 영역 림프절을 포함하는 부위에 45 Gy를 조사한 후 원발병소가 있었던 부위를 중심으로 조사범위를 축소하여 $5.4{\sim}9\;Gy$를 추가조사 하였다. 추적관찰기간은 $8{\sim}75$개월이었고 중앙값은 35개월이었다. 결 과: 전체 46명 중 17명(37%)에서 재발이 관찰되었다. 국소단독실패는 없었고 영역단독실패 1명(2.2%), 원격단독 실패 13명(28.3%), 국소영역 및 원격실패 3명(6.5%)으로 국소영역실패율은 8.7%, 원격실패율은 34.8%였다. 최초 치료실패 부위는 골반 내 원발병소 주변 부위와 골반 내 림프절이 각각 3명이었고 연결부위나 회음부에서 실패한 경우는 없었다. 최초 원격실패의 부위는 폐, 간, 뼈 순이었다. 전체 5년 생존율과 무재발 생존율은 각각 51.5%와 58.7%였다. N 병기에 따른 생존율은 N0, N1, N2에서 각각 100%, 53.7%, 0%였고(p=0.012), 무재발 생존율은 각각 100%, 47.6%, 41.2%였다(p=0.009). 종양의 위치에 따른 무재발 생존율은 상부, 중간부, 하부에서 각각 55.0%, 78.5%, 31.2%였다(p=0.006). 다변량 분석에서 5년 전체 생존율에 영향을 미치는 유의한 예후인자는 N 병기였고(p=0.012), 무재발 생존율에 영향을 미치는 예후인자는 N 병기와(p=0.001) 종양의 위치였다(p=0.006). 수술을 요하는 장 관련 후유증은 3명(6.5%)에서 발생하였다. 결 론: 직장암의 치료에서 근치적 수술 후 보조 화학방사선요법은 국소영역제어 측면에서는 효과적이었으나 원격제어에 대한 효과는 부족하다고 생각된다. 향후 생존율을 더욱 향상시키기 위해서는 원격실패를 감소시키려는 노력이 시도되어야 될 것으로 생각한다.

Keywords

References

  1. Rich T, Gunderson LL, Lew R, Galdibini JJ, Cohen AM, Donaldson G. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 1983;52:1317-1329 https://doi.org/10.1002/1097-0142(19831001)52:7<1317::AID-CNCR2820520731>3.0.CO;2-6
  2. Pilipshen SJ, Heilweil M, Quan SH, Sternberg SS, Enker WE. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 1984;53:1354-1362 https://doi.org/10.1002/1097-0142(19840315)53:6<1354::AID-CNCR2820530623>3.0.CO;2-J
  3. Minsky BD, Mies C, Recht A, Rich TA, Chaffey JT. Resectable adenocarcinoma of the rectosigmoid and rectum. I. Patterns of failure and survival. Cancer 1988;61:1408-1416 https://doi.org/10.1002/1097-0142(19880401)61:7<1408::AID-CNCR2820610722>3.0.CO;2-A
  4. Ghossein NA, Sarnala EC, Alpert S, et al. Elective postoperative radiotherapy after incomplete resection of colorectal cancer. Dis Colon Rectum 1981;24:252-256 https://doi.org/10.1007/BF02641870
  5. Brizel HE, Tepperrnan BS. Postoperative adjuvant irradiation for adenocarcinoma of the rectum and sigmoid. Am J Clin Oncol 1984;7:679-685 https://doi.org/10.1097/00000421-198412000-00016
  6. Hoskins RB, Gunderson LL, Dosoretz DE, et al. Adjuvant postoperative radiotherapy in carcinoma of the rectum and rectosigmoid. Cancer 1985;55:61-71 https://doi.org/10.1002/1097-0142(19850101)55:1<61::AID-CNCR2820550111>3.0.CO;2-Z
  7. Mohiuddin M, Derdel J, Marks G, Krarner S. Results of adjuvant radiation therapy in cancer of the rectum. Thomas Jefferson University Hospital experience. Cancer 1985;55:350-353 https://doi.org/10.1002/1097-0142(19850115)55:2<350::AID-CNCR2820550208>3.0.CO;2-3
  8. Gastrointestinal Turnor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985;312:1465-1472 https://doi.org/10.1056/NEJM198506063122301
  9. Tepper JE, Cohen AM, Wood WC, Orlow EL, Hedberg SE. Postoperative radiation therapy of rectal cancer. Int J Radiat Oncol Biol Phys 1987;13:5-10 https://doi.org/10.1016/0360-3016(87)90252-5
  10. Vigliotti A, Rich TA, Rornsdahl MM, Withers HR, Oswald MJ. Postoperative adjuvant radiotherapy for adenocarcinoma of the rectum and rectosigmoid. Int J Radiat Oncol Biol Phys 1987; 13:999-1 006 https://doi.org/10.1016/0360-3016(87)90037-X
  11. Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988; 80:21-29 https://doi.org/10.1093/jnci/80.1.21
  12. Schild SE, Martenson JA Jr, Gunderson SS, et al. Postoperative adjuvant therapy of rectal cancer: an analysis of disease control, survival, and prognostic factors. Int J Radiat Oncol Biol Phys 1989;17:55-62 https://doi.org/10.1016/0360-3016(89)90370-2
  13. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-715 https://doi.org/10.1056/NEJM199103143241101
  14. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-1450
  15. Wolmark N, Wieand HS, Hyams DM, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000;92:388-396 https://doi.org/10.1093/jnci/92.5.388
  16. Pazdur R, Douillard JY, Skillings J, et al. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:263a
  17. Carmichael J, Popiela T, Radstone D, et al. Randomized com parative study of Orzel (oral uracil/tegafur (UFT) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:264a
  18. Kato T, Ohashi Y, Nakazato H, et al. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbecks Arch Surg 2002;386:575-581 https://doi.org/10.1007/s00423-002-0278-x
  19. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115 https://doi.org/10.1200/JCO.1997.15.1.110
  20. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-2292 https://doi.org/10.1200/JCO.2001.19.8.2282
  21. Van Cutsern V, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-4106 https://doi.org/10.1200/JCO.2001.19.21.4097
  22. Miller AR, Martenson JA, Nelson H, et al. The incidence and clinical consequences of treatment-related bowel injury. Int J Radiat Oncol Biol Phys 1999;43:817-825 https://doi.org/10.1016/S0360-3016(98)00485-4
  23. Kirn YS, Kirn JH, Choi EK, et al. Optimal scheme of postoperative chemoradiotherapy in rectal cancer: phase III prospective randomized trial. J Korean Soc Ther Radiol Oncol 2002; 20:53-61
  24. Chai GY, Kang KM, Choi SG. Postoperative chemoradiotherapy in locally advanced rectal cancer. J Korean Soc Ther Radiol Oncol 2002;20:221-227